Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program - Concepedia

Concepedia

Publication | Open Access

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

DOI Full Paper Access

115

Citations

39

References

2014

Year

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups,

Clinical Cancer Research

Abstract

The high level of activity observed for talazoparib plus temozolomide in Ewing sarcoma xenografts makes this an interesting combination to consider for pediatric evaluation.

References

	Year	Citations

Page 1